Research programme: serine hydrolase inhibitors - Abide Therapeutics

Drug Profile

Research programme: serine hydrolase inhibitors - Abide Therapeutics

Latest Information Update: 06 Nov 2014

Price : $50

At a glance

  • Originator Abide Therapeutics
  • Developer Abide Therapeutics; Oxford University Hospitals NHS Trust; University of California, San Diego; University of Oxford
  • Class Small molecules
  • Mechanism of Action Hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Down syndrome
  • Research Brain disorders

Most Recent Events

  • 04 Nov 2014 Early research in Brain disorders in United Kingdom (unspecified route)
  • 04 Nov 2014 Abide Therapeutics enters into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust for the development of MAGL inhibitors for Brain disorders
  • 16 Jul 2013 Preclinical trials in Down syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top